\nInnoviva, Inc. (NASDAQ: INVA) (\u201cInnoviva\u201d or \u201cthe Company\u201d), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the first quarter ended March 31, 2023, highlighted select corporate achievements and provided an overview of its key business initiatives.<\/p>\n
- \n
- \nGross royalty revenue from Glaxo Group Limited (GSK) for the first quarter 2023 was $60.3 million, which included royalties of $50.9 million from global net sales of RELVAR\u00ae\/BREO\u00ae ELLIPTA\u00ae and royalties of $9.4 million from global net sales of ANORO\u00ae ELLIPTA\u00ae, compared to $93.5 million for the first quarter of 2022. The decrease was primarily due to the sale of our subsidiary, Theravance Respiratory Company, with its TRELEGY\u00ae royalty stream in July 2022.<\/p>\n<\/li>\n<\/ul>\n
- \n
- \nNet product sales and license revenue for the first quarter of 2023 was $19.5 million, which included $9.0 million from GIAPREZA\u00ae net sales, $2.5 million from XERAVA\u00ae net sales and an $8.0 million milestone payment from our partner for the approval of XERAVA\u00ae in mainland China.<\/p>\n<\/li>\n<\/ul>\n
- \n
- \nNet income was $34.9 million, or $0.51 basic per share, for the first quarter of 2023, compared to net income of $15.8 million, or $0.23 basic per share, for the first quarter of 2022.<\/p>\n<\/li>\n<\/ul>\n
- \n
- \nCash and cash equivalents totaled $144.0 million. Royalty, product sales and milestone receivables totaled $75.8 million as of March 31, 2023.<\/p>\n<\/li>\n<\/ul>\n
\n“The first quarter of 2023 was marked by strong revenues stemming from both our royalty portfolio and our internal product portfolio along with continued execution against key corporate objectives,\u201d said Pavel Raifeld, Chief Executive Officer of Innoviva. \u201cAlso of note, the U.S. Food and Drug Administration\u2019s Antimicrobial Drugs Advisory Committee recently returned a unanimous vote in support of approval for sulbactam-durlobactam in adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. We believe this is a critical step toward bringing this much needed treatment to patients with these life-threatening infections caused by Acinetobacter Baumannii-calcoaceticus<\/i> complex. We are disciplined with regard to managing costs and focused on realizing synergies from our operating platform. We remain excited about the prospects of our business and continue to pursue shareholder value accretive activities, such as share repurchases.\u201d<\/p>\n
First Quarter 2023 and Recent Highlights<\/b><\/p>\n
GSK Net Sales<\/i><\/p>\n
- \n
- \nFirst quarter 2023 net sales of RELVAR\u00ae\/BREO\u00ae ELLIPTA\u00ae by GSK were $339.2 million with $122.4 million in net sales from the U.S. market and $216.8 million from non-U.S. markets.<\/p>\n<\/li>\n<\/ul>\n
- \n
- \nFirst quarter 2023 net sales of ANORO\u00ae ELLIPTA\u00ae by GSK were $145.1 million with $62.2 million net sales from the U.S. market and $82.9 million from non-U.S. markets.<\/p>\n<\/li>\n<\/ul>\n
Corporate Updates<\/i><\/p>\n
- \n
- \nInnoviva\u2019s recently established subsidiary, Innoviva Specialty Therapeutics, which integrated Entasis Therapeutics Holding Inc (\u201cEntasis\u201d) and La Jolla Pharmaceutical Company and, in conjunction with its affiliates, markets GIAPREZA\u00ae and XERAVA\u00ae as well as advances the development and commercialization of sulbactam-durlobactam and zoliflodacin.<\/p>\n<\/li>\n<\/ul>\n
- \n
- \nOn January 10, 2023, the Company\u2019s wholly owned subsidiary, Innoviva Strategic Opportunities LLC, invested $30.0 million in a convertible promissory note of Armata Pharmaceuticals, Inc. to support the clinical development of its multiple innovative bacteriophage assets as well as advanced biologics cGMP manufacturing capabilities.<\/p>\n<\/li>\n<\/ul>\n
- \n
- \nOn February 2, 2023, the Company\u2019s wholly owned subsidiary, Innoviva TRC Holding LLC, invested $5.0 million in a convertible promissory note of Gate Neurosciences Inc. to support the clinical development of its differentiated pipeline of neuropsychiatric therapeutics.<\/p>\n<\/li>\n<\/ul>\n
- \n
- \nDuring the first quarter of 2023, Innoviva repurchased approximately 3.4 million shares of its outstanding common stock for $40.3 million.<\/p>\n<\/li>\n<\/ul>\n
- \n
- \nIn January 2023, Innoviva paid off the remaining principal balance of $96.2 million of its convertible subordinated notes, due 2023.<\/p>\n<\/li>\n<\/ul>\n
Clinical Updates<\/i><\/p>\n
- \n
- \nOn April 17, 2023, the FDA\u2019s Antimicrobial Drugs Advisory Committee (AMDAC) unanimously voted 12-0 in support of approval of sulbactam-durlobactam based on a favorable benefit-risk assessment for the treatment of adults with hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible strains of Acinetobacter baumannii-calcoaceticus<\/i> complex (Acinetobacter<\/i>). The sulbactam-durlobactam New Drug Application (NDA), filed by Entasis, was accepted and granted Priority Review by the FDA in November 2022, with a Prescription Drug User Fee Act (PDUFA) target action date of May 29, 2023.<\/p>\n<\/li>\n<\/ul>\n
- \n
- \nPhase 3 Zoliflodacin study on track to complete enrollment in second half of 2023. Zoliflodacin is a novel, first-in-class oral antibiotic in development for the treatment of uncomplicated gonorrhea.<\/p>\n<\/li>\n<\/ul>\n
About Innoviva<\/b><\/p>\n
\nInnoviva is a diversified holding company with a portfolio of royalties and other healthcare assets. Innoviva\u2019s royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (\u201cGSK\u201d), including RELVAR\u00ae<\/sup>\/BREO\u00ae<\/sup> ELLIPTA\u00ae<\/sup> (fluticasone furoate\/ vilanterol, \u201cFF\/VI\u201d) and ANORO\u00ae<\/sup> ELLIPTA\u00ae<\/sup> (umeclidinium bromide\/ vilanterol, \u201cUMEC\/VI\u201d). Under the Long-Acting Beta2 Agonist (\u201cLABA\u201d) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR\u00ae<\/sup>\/BREO\u00ae<\/sup> ELLIPTA\u00ae<\/sup> and ANORO\u00ae<\/sup> ELLIPTA\u00ae<\/sup>. Innoviva\u2019s other healthcare assets include infectious disease and hospital assets stemming from acquisitions of Entasis Therapeutics, including its lead asset sulbactam-durlobactam, and La Jolla Pharmaceutical, including GIAPREZA\u00ae (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA\u00ae (eravacycline) for the treatment of complicated intra-abdominal infections in adults.<\/p>\n
\nANORO\u00ae<\/sup>, RELVAR\u00ae<\/sup> and BREO\u00ae<\/sup> are trademarks of the GSK group of companies.<\/p>\n
Forward Looking Statements<\/b><\/p>\n
\nThis press release contains certain \u201cforward-looking\u201d statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives, and future events. Innoviva intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. The words \u201canticipate\u201d, \u201cexpect\u201d, \u201cgoal\u201d, \u201cintend\u201d, \u201cobjective\u201d, \u201copportunity\u201d, \u201cplan\u201d, \u201cpotential\u201d, \u201ctarget\u201d and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements involve substantial risks, uncertainties, and assumptions. These statements are based on the current estimates and assumptions of the management of Innoviva as of the date of this press release and are subject to known and unknown risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Innoviva to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: expected cost savings; lower than expected future royalty revenue from respiratory products partnered with GSK; the commercialization of RELVAR\u00ae<\/sup>\/BREO\u00ae<\/sup> ELLIPTA\u00ae<\/sup>, ANORO\u00ae<\/sup> ELLIPTA\u00ae<\/sup>, GIAPREZA\u00ae<\/sup> and XERAVA\u00ae<\/sup> in the jurisdictions in which these products have been approved; the strategies, plans and objectives of Innoviva (including Innoviva\u2019s growth strategy and corporate development initiatives); the timing, manner, and amount of potential capital returns to shareholders; the status and timing of clinical studies, data analysis and communication of results; the potential benefits and mechanisms of action of product candidates; expectations for product candidates through development and commercialization; the timing of regulatory approval of product candidates; and projections of revenue, expenses and other financial items; the impact of the novel coronavirus (\u201cCOVID-19\u201d); the timing, manner and amount of capital deployment, including potential capital returns to stockholders; and risks related to the Company\u2019s growth strategy. Other risks affecting Innoviva are described under the headings \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations\u201d contained in Innoviva\u2019s Annual Report on Form 10-K for the year ended December 31, 2022 and Quarterly Reports on Form 10-Q, which are on file with the Securities and Exchange Commission (\u201cSEC\u201d) and available on the SEC\u2019s website at www.sec.gov<\/a>. Past performance is not necessarily indicative of future results. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The information in this press release is provided only as of the date hereof, and Innoviva assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.<\/p>\n
\n
\n \n \nINNOVIVA, INC.<\/p>\n<\/td>\n<\/tr>\n
\n \n \nCondensed Consolidated Statements of Income<\/p>\n<\/td>\n<\/tr>\n
\n \n \n(in thousands, except per share data)<\/p>\n<\/td>\n<\/tr>\n
\n \n \n(Unaudited)<\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n \n \nThree Months Ended<\/p>\n<\/td>\n<\/tr>\n
\n \n \n \nMarch 31,<\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n \n2023<\/p>\n<\/td>\n
\n \n \n2022<\/p>\n<\/td>\n<\/tr>\n
\n Revenue:<\/td>\n \n \n \n <\/tr>\n \n Royalty revenue, net (1)<\/td>\n \n \n \n$<\/p>\n<\/td>\n
\n \n56,858<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n90,059<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Net product sales<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n11,514<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n–<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n License revenue<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n8,000<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n–<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Total revenue<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n76,372<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n90,059<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Expenses:<\/td>\n \n \n \n <\/tr>\n \n Cost of products sold (inclusive of amortization of inventory fair value adjustments, excluding depreciation and amortization of intangible assets)<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n8,749<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n–<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Cost of license revenue<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n1,600<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n–<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Selling, general and administrative<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n19,735<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n6,492<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Research and development<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n12,588<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n5,838<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Amortization of acquired intangible assets<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n3,805<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n–<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Loss on debt extinguishment<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n–<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n20,662<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Changes in fair values of equity method investments, net<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(15,817<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n11,950<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Changes in fair values of equity and long-term investments, net<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n2,164<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(2,539<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n<\/tr>\n
\n Interest and dividend income<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(3,365<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(322<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n<\/tr>\n
\n Interest expense<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n4,427<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n3,010<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Other expense, net<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n1,346<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n250<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Total expenses<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n35,232<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n45,341<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Income before income taxes<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n41,140<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n44,718<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Income tax expense<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n6,275<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n6,860<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Net income<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n34,865<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n37,858<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Net income attributable to noncontrolling interest<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n–<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n22,085<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Net income attributable to Innoviva stockholders<\/td>\n \n \n \n$<\/p>\n<\/td>\n
\n \n34,865<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n15,773<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n Basic net income per share attributable to Innoviva stockholders<\/td>\n \n \n \n$<\/p>\n<\/td>\n
\n \n0.51<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n0.23<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Diluted net income per share attributable to Innoviva stockholders<\/td>\n \n \n \n$<\/p>\n<\/td>\n
\n \n0.42<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n0.20<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n Shares used to compute basic net income per share<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n67,786<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n69,544<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Shares used to compute diluted net income per share<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n89,788<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n93,730<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n
\n
\n (1) Total net revenue is comprised of the following (in thousands):<\/td>\n \n \n \n <\/tr>\n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n \n \nThree Months Ended<\/p>\n<\/td>\n<\/tr>\n
\n \n \n \nMarch 31,<\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n \n2023<\/p>\n<\/td>\n
\n \n \n2022<\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n \n(unaudited)<\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n Royalties<\/td>\n \n \n \n$<\/p>\n<\/td>\n
\n \n60,314<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n93,515<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Amortization of capitalized fees<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(3,456<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(3,456<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n<\/tr>\n
\n Royalty revenue, net<\/td>\n \n \n \n$<\/p>\n<\/td>\n
\n \n56,858<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n90,059<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n<\/table>\n \n
\n \n \nINNOVIVA, INC.<\/p>\n<\/td>\n<\/tr>\n
\n \n \nCondensed Consolidated Balance Sheets<\/p>\n<\/td>\n<\/tr>\n
\n \n \n(in thousands)<\/p>\n<\/td>\n<\/tr>\n
\n \n \n(unaudited)<\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n \n \nMarch 31,<\/p>\n<\/td>\n
\n \n \nDecember 31,<\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n \n2023<\/p>\n<\/td>\n
\n \n \n2022<\/p>\n<\/td>\n<\/tr>\n
\n Assets<\/td>\n \n \n \n <\/tr>\n \n Cash and cash equivalents<\/td>\n \n \n \n$<\/p>\n<\/td>\n
\n \n144,049<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n291,049<\/p>\n<\/td>\n<\/tr>\n
\n Royalty and product sale receivables<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n75,804<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n64,073<\/p>\n<\/td>\n<\/tr>\n
\n Inventory, net<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n49,653<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n55,897<\/p>\n<\/td>\n<\/tr>\n
\n Prepaid expense and other current assets<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n26,940<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n32,492<\/p>\n<\/td>\n<\/tr>\n
\n Property and equipment, net<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n180<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n170<\/p>\n<\/td>\n<\/tr>\n
\n Equity and long-term investments<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n455,865<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n403,013<\/p>\n<\/td>\n<\/tr>\n
\n Capitalized fees<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n94,151<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n97,607<\/p>\n<\/td>\n<\/tr>\n
\n Right-of-use assets<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n2,973<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n3,265<\/p>\n<\/td>\n<\/tr>\n
\n Goodwill<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n27,946<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n26,713<\/p>\n<\/td>\n<\/tr>\n
\n Intangible assets<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n248,314<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n252,919<\/p>\n<\/td>\n<\/tr>\n
\n Other assets<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n3,893<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n4,299<\/p>\n<\/td>\n<\/tr>\n
\n Total assets<\/td>\n \n \n \n$<\/p>\n<\/td>\n
\n \n1,129,768<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n1,231,497<\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n Liabilities and stockholders\u2019 equity<\/td>\n \n \n \n <\/tr>\n \n Other current liabilities<\/td>\n \n \n \n$<\/p>\n<\/td>\n
\n \n35,210<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n32,322<\/p>\n<\/td>\n<\/tr>\n
\n Accrued interest payable<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n833<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n4,359<\/p>\n<\/td>\n<\/tr>\n
\n Deferred revenue<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n2,094<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n2,094<\/p>\n<\/td>\n<\/tr>\n
\n Convertible subordinated notes, due 2023, net<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n–<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n96,193<\/p>\n<\/td>\n<\/tr>\n
\n Convertible senior notes, due 2025, net<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n190,759<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n190,583<\/p>\n<\/td>\n<\/tr>\n
\n Convertible senior notes, due 2028, net<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n253,933<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n253,597<\/p>\n<\/td>\n<\/tr>\n
\n Other long term liabilities<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n70,133<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n70,918<\/p>\n<\/td>\n<\/tr>\n
\n Deferred tax liabilities<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n5,392<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n5,771<\/p>\n<\/td>\n<\/tr>\n
\n Income tax payable – long term<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n9,921<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n9,872<\/p>\n<\/td>\n<\/tr>\n
\n Innoviva stockholders\u2019 equity<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n561,493<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n565,788<\/p>\n<\/td>\n<\/tr>\n
\n Total liabilities and stockholders\u2019 equity<\/td>\n \n \n \n$<\/p>\n<\/td>\n
\n \n1,129,768<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n1,231,497<\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n<\/table>\n \n
\n INNOVIVA, INC.<\/td>\n<\/tr>\n \n \n \nCash Flows Summary<\/p>\n<\/td>\n<\/tr>\n
\n \n \n(in thousands)<\/p>\n<\/td>\n<\/tr>\n
\n \n \n(unaudited)<\/p>\n<\/td>\n<\/tr>\n
\n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n \n \nThree Months Ended March 31,<\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n \n2023<\/p>\n<\/td>\n
\n \n \n2022<\/p>\n<\/td>\n<\/tr>\n
\n Net cash provided by operating activities<\/td>\n \n \n \n$<\/p>\n<\/td>\n
\n \n25,684<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n98,102<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Net cash used in investing activities<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(35,722<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(143,156<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n<\/tr>\n
\n Net cash (used in) provided by financing activities<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(136,962<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n60,331<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Net change<\/td>\n \n \n \n$<\/p>\n<\/td>\n
\n \n(147,000<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n15,277<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Cash and cash equivalents at beginning of period<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n291,049<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n201,525<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Cash, cash equivalents and restricted cash at end of period<\/td>\n \n \n \n$<\/p>\n<\/td>\n
\n \n144,049<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n216,802<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n
\n\u00a0<\/p>\n
<\/p>\n
View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230509006103\/en\/<\/a><\/span><\/p>\n
- \nPhase 3 Zoliflodacin study on track to complete enrollment in second half of 2023. Zoliflodacin is a novel, first-in-class oral antibiotic in development for the treatment of uncomplicated gonorrhea.<\/p>\n<\/li>\n<\/ul>\n
- \nOn April 17, 2023, the FDA\u2019s Antimicrobial Drugs Advisory Committee (AMDAC) unanimously voted 12-0 in support of approval of sulbactam-durlobactam based on a favorable benefit-risk assessment for the treatment of adults with hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible strains of Acinetobacter baumannii-calcoaceticus<\/i> complex (Acinetobacter<\/i>). The sulbactam-durlobactam New Drug Application (NDA), filed by Entasis, was accepted and granted Priority Review by the FDA in November 2022, with a Prescription Drug User Fee Act (PDUFA) target action date of May 29, 2023.<\/p>\n<\/li>\n<\/ul>\n
- \nIn January 2023, Innoviva paid off the remaining principal balance of $96.2 million of its convertible subordinated notes, due 2023.<\/p>\n<\/li>\n<\/ul>\n
- \nDuring the first quarter of 2023, Innoviva repurchased approximately 3.4 million shares of its outstanding common stock for $40.3 million.<\/p>\n<\/li>\n<\/ul>\n
- \nOn February 2, 2023, the Company\u2019s wholly owned subsidiary, Innoviva TRC Holding LLC, invested $5.0 million in a convertible promissory note of Gate Neurosciences Inc. to support the clinical development of its differentiated pipeline of neuropsychiatric therapeutics.<\/p>\n<\/li>\n<\/ul>\n
- \nOn January 10, 2023, the Company\u2019s wholly owned subsidiary, Innoviva Strategic Opportunities LLC, invested $30.0 million in a convertible promissory note of Armata Pharmaceuticals, Inc. to support the clinical development of its multiple innovative bacteriophage assets as well as advanced biologics cGMP manufacturing capabilities.<\/p>\n<\/li>\n<\/ul>\n
- \nInnoviva\u2019s recently established subsidiary, Innoviva Specialty Therapeutics, which integrated Entasis Therapeutics Holding Inc (\u201cEntasis\u201d) and La Jolla Pharmaceutical Company and, in conjunction with its affiliates, markets GIAPREZA\u00ae and XERAVA\u00ae as well as advances the development and commercialization of sulbactam-durlobactam and zoliflodacin.<\/p>\n<\/li>\n<\/ul>\n
- \nFirst quarter 2023 net sales of ANORO\u00ae ELLIPTA\u00ae by GSK were $145.1 million with $62.2 million net sales from the U.S. market and $82.9 million from non-U.S. markets.<\/p>\n<\/li>\n<\/ul>\n
- \nFirst quarter 2023 net sales of RELVAR\u00ae\/BREO\u00ae ELLIPTA\u00ae by GSK were $339.2 million with $122.4 million in net sales from the U.S. market and $216.8 million from non-U.S. markets.<\/p>\n<\/li>\n<\/ul>\n
- \nCash and cash equivalents totaled $144.0 million. Royalty, product sales and milestone receivables totaled $75.8 million as of March 31, 2023.<\/p>\n<\/li>\n<\/ul>\n
- \nNet income was $34.9 million, or $0.51 basic per share, for the first quarter of 2023, compared to net income of $15.8 million, or $0.23 basic per share, for the first quarter of 2022.<\/p>\n<\/li>\n<\/ul>\n
- \nNet product sales and license revenue for the first quarter of 2023 was $19.5 million, which included $9.0 million from GIAPREZA\u00ae net sales, $2.5 million from XERAVA\u00ae net sales and an $8.0 million milestone payment from our partner for the approval of XERAVA\u00ae in mainland China.<\/p>\n<\/li>\n<\/ul>\n